Literature DB >> 16157026

Experimental study on anti-neoplastic activity of epigallocatechin-3-gallate to digestive tract carcinomas.

Zhi-hua Ran1, Jian Zou, Shu-dong Xiao.   

Abstract

BACKGROUND: Epigallocatechin-3-gallate (EGCG) has been demonstrated to have anti-neoplastic activity, but the effective concentration of EGCG and its possible mechanisms are uncertain. The study on the killing effects of EGCG on different digestive tract cancer cell lines can find target sites of its anti-neoplastic effect and provide a theoretical basis for its clinical application in the treatment of cancers.
METHODS: Methyl thiazolyl tetrazolium (MTT) analysis was made to detect the differential sensitivities of eight digestive tract cancer cell lines to EGCG. The effect of EGCG on cell cycle distribution of sensitive cancer cell line was measured by flow cytometry. By polymerase chain reaction (PCR)-enzyme linked immunosorbent assay (ELISA) protocol, the influence of EGCG on telomerase activity of sensitive cancer cell line was also investigated. RT-PCR method was employed to detect the influence of EGCG on the expressions of hTERT, c-myc, p53 and mad1 genes in sensitive cancer cell line.
RESULTS: EGCG exhibited dose-dependent killing effects on all eight digestive tract cancer cell lines. The 50% inhibitory concentration (IC50) of SW1116, MKN45, BGC823, SGC7901, AGS, MKN28, HGC27 and LoVo cells were 51.7 micromol/L, 55.9 micromol/L, 68.5 micromol/L, 79.1 micromol/L, 83.8 micromol/L, 119.8 micromol/L, 183.2 micromol/L and 194.6 micromol/L, respectively. There were no apparent changes in cell cycle distribution of sensitive cancer cell line MKN45 48 hours after incubating with three different concentrations of EGCG compared with the controls. It was found that EGCG could suppress the telomerase activity of MKN45 cells, and the effects were dose- and time-dependent. After EGCG administration, the expression of hTERT and c-myc genes in MKN45 cells was decreased, that of the mad1 gene increased, and that of the p53 gene unchanged.
CONCLUSIONS: EGCG has dose-dependent killing effects on different digestive tract cancer cell lines. Administration of EGCG has no obvious effect on cell cycle distribution of sensitive cancer cell line MKN45. The anti-neoplastic activity of EGCG might be due to the inhibition of telomerase activity by means of its influence on hTERT and the up-stream regulation genes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16157026

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  4 in total

1.  An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules.

Authors:  Amrita Basu; Nicole E Bodycombe; Jaime H Cheah; Edmund V Price; Ke Liu; Giannina I Schaefer; Richard Y Ebright; Michelle L Stewart; Daisuke Ito; Stephanie Wang; Abigail L Bracha; Ted Liefeld; Mathias Wawer; Joshua C Gilbert; Andrew J Wilson; Nicolas Stransky; Gregory V Kryukov; Vlado Dancik; Jordi Barretina; Levi A Garraway; C Suk-Yee Hon; Benito Munoz; Joshua A Bittker; Brent R Stockwell; Dineo Khabele; Andrew M Stern; Paul A Clemons; Alykhan F Shamji; Stuart L Schreiber
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

Review 2.  The chemopreventive and chemotherapeutic potentials of tea polyphenols.

Authors:  Vijay S Thakur; Karishma Gupta; Sanjay Gupta
Journal:  Curr Pharm Biotechnol       Date:  2012-01       Impact factor: 2.837

Review 3.  Epigenetic modifications by dietary phytochemicals: implications for personalized nutrition.

Authors:  Sharmila Shankar; Dhruv Kumar; Rakesh K Srivastava
Journal:  Pharmacol Ther       Date:  2012-11-16       Impact factor: 12.310

4.  Catechins induced acute promyelocytic leukemia cell apoptosis and triggered PML-RARα oncoprotein degradation.

Authors:  Li Zhang; Qiu-Sheng Chen; Peng-Peng Xu; Ying Qian; Ai-Hua Wang; Dan Xiao; Yan Zhao; Yan Sheng; Xiang-Qin Wen; Wei-Li Zhao
Journal:  J Hematol Oncol       Date:  2014-10-01       Impact factor: 17.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.